Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ELCC 2019 | Second-generation ALK inhibitors in ALK-positive NSCLC

Antonio Passaro • 16 Apr 2019
ELCC 2019
Lung Cancer Non-Small Cell Lung Cancer Brigatinib

Antonio Passaro, MD, PhD, of European Institute of Oncology IRCCS, Milan, Italy, talks about the survival benefits brought by second-generation ALK inhibitors in patients with ALK-positive non-small cell lung cancer (NSCLC). This video was recorded at the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland.

More from Antonio Passaro

2:04
MARIPOSA-2: amivantamab + chemo (± lazertinib) vs chemo in EGFR-mutated NSCLC post-osimertinib
Antonio Passaro • 22 Oct 2023
1:35
Afatinib for advanced EGFRm-positive NSCLC
Antonio Passaro • 7 May 2019
0:44
ALK-TKIs: targeted therapies for ALK-positive NSCLC
Antonio Passaro • 16 Apr 2019

Related Videos

2:38
Phase I trial of binimetinib and pembrolizumab in NSCLC
Natasha Leighl • 17 Apr 2024
2:43
CHRYSALIS: amivantamab in wild-type, pre-treated NSCLC
Natasha Leighl • 17 Apr 2024
3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
2:09
Is there a role for radiotherapy in extensive-stage SCLC?
Clive Peedell • 18 Apr 2024
The content of VJOncology is intended for healthcare professionals